We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GRASSLEY RAMPS UP DRUG REVIEW INVESTIGATION

GRASSLEY RAMPS UP DRUG REVIEW INVESTIGATION

May 18, 2006

Sen. Chuck Grassley (R-Iowa), the Senate Finance Committee chairman and a frequent FDA critic, is ramping up his investigation of the FDA's handling of sanofi-aventis' Ketek (telithromycin), arguing that the agency has been uncooperative in responding to earlier information requests.

Grassley previously argued in an April 27 letter that the FDA's review of Ketek was inadequate and relied on the company's allegedly fraudulent safety study. The senator has argued that the Ketek case was important because the agency's handling of this drug was indicative of flaws in its overall drug review system.

The senator has sought all data about the Ketek study, including administrative files from the agency's review of the study and a full briefing on the issue by agency staff. But the agency has been unresponsive to these requests, leading Grassley to send a recent letter to the FDA seeking more information, his spokeswoman Jill Kozeny said. "The FDA has an obligation to be forthcoming and open about its actions," Grassley said.

Now Grassley is also requesting an interview with the special agent in charge of the Ketek case and wants the FDA to turn over all documents related to that investigation. "Given the gravity of the Ketek allegations, I respectfully request that your staff contact my staff by no later than Thursday, May 18, 2006, to make arrangements for this interview and for the committee to obtain the requested documents from Special Agent [name withheld] by no later than May 24, 2006," he said.

The senator is also renewing his call on agency staff to feel free to serve as whistleblowers when they have concerns with FDA policy. In his April 27 letter, Grassley instructed the agency to inform their employees of their right to speak and to cooperate with Congress. FDA employees should also contact Congress if they believe the agency has retaliated against them for such cooperation, he said. (http://www.fdanews.com/did/5_97/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

  • Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

  • FDA Issues Update on Becton Dickinson’s Recall

  • FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing